Teva Pharmaceutical Industries (TEVA) Retained Earnings (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Retained Earnings came in at $28.3 billion in Q2 2026, up 0.9% YoY from $28.0 billion in Q2 2025, and little changed on a QoQ basis from $28.2 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Retained Earnings (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Retained Earnings data on file, last reported at $28.3 billion in Q2 2026.
- Quarterly Retained Earnings rose 0.9% year-over-year to $28.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $28.3 billion (up 0.9% YoY) and the FY2025 annual result came in at $28.1 billion, up 1.33% from the prior year.
- Retained Earnings was little changed at $28.3 billion in Q2 2026, from $28.2 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $28.3 billion in Q2 2026 to a low of -$14.1 billion in Q2 2023.
- A 5-year average of $10.4 billion and a median of $12.5 billion in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 379.72% — and 2024, when it soared 1129.44%.
- Tracing TEVA's Retained Earnings over 5 years: stood at -$2.8 billion in 2022, then advanced by 4.97% to -$2.7 billion in 2023, then soared by 1129.44% to $27.8 billion in 2024, then rose by 1.33% to $28.1 billion in 2025, then advanced by 0.44% to $28.3 billion in 2026.
- The last three Retained Earnings figures came in at $28.3 billion (Q2 2026), $28.2 billion (Q1 2026), and $28.1 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 3.75 Bn |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | -800.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.26 Bn |
| Mar 31, 2026 | 28.20 Bn |
| Dec 31, 2025 | 28.13 Bn |
| Sep 30, 2025 | 28.04 Bn |
| Jun 30, 2025 | 28.00 Bn |
| Mar 31, 2025 | 27.97 Bn |
| Dec 31, 2024 | 27.76 Bn |
| Sep 30, 2024 | 27.86 Bn |
| Jun 30, 2024 | 27.83 Bn |
| Mar 31, 2024 | -2.78 Bn |
| Dec 31, 2023 | -2.70 Bn |
| Sep 30, 2023 | -14.00 Bn |
| Jun 30, 2023 | -14.07 Bn |
| Mar 31, 2023 | -2.70 Bn |
| Dec 31, 2022 | -2.84 Bn |
| Sep 30, 2022 | -11.67 Bn |
| Jun 30, 2022 | -11.73 Bn |
| Mar 31, 2022 | -2.69 Bn |
| Dec 31, 2021 | -2.68 Bn |
| Sep 30, 2021 | -2.62 Bn |